Rezolute, Inc. Provides Update on Congenital Hyperinsulinism Program Following FDA Meeting
Rezolute, Inc. Provides Update on Congenital Hyperinsulinism Program Following FDA Meeting
Key Highlights
-
Rezolute held a pivotal in-person Type B meeting with the U.S. Food and Drug Administration (FDA) on March 17, 2026, to discuss the latest data from the sunRIZE Phase 3 trial and ongoing open-label extension (OLE) for ersodetug in congenital hyperinsulinism (HI).
-
The FDA encouraged Rezolute to submit comprehensive data from both sunRIZE and the OLE for independent agency review, with the potential for a future marketing application if evidence supports it.
-
sunRIZE demonstrated reductions in hypoglycemia events from baseline, but did not meet its primary endpoint due to lack of statistical significance versus placebo, which the company attributes to a “pronounced study effect.”
-
Notably, although the primary endpoint was missed, clinically meaningful improvements in time spent in hypoglycemia (measured by continuous glucose monitoring, CGM) were observed, and ongoing OLE data show continued improvement in patients.
-
The FDA did not dismiss the program outright and acknowledged the challenges in measuring hypoglycemia in this heterogeneous patient population, particularly due to behavioral factors and limitations of self-monitored blood glucose (SMBG) metrics.
-
The agency reaffirmed the need for adequate and well-controlled studies, but was receptive to reviewing all available data for potential advancement of the program.
-
Rezolute anticipates providing an update on the program in the second half of 2026.
Detailed Report
Rezolute, Inc. (Nasdaq: RZLT), a late-stage rare disease company focused on therapies for hypoglycemia caused by hyperinsulinism (HI), has provided a significant update following an in-person FDA meeting regarding its lead program, ersodetug, for congenital HI.
The meeting centered on results from sunRIZE, a Phase 3, double-blind, placebo-controlled study of ersodetug, and additional data from the ongoing open-label extension. In December 2025, Rezolute reported that sunRIZE showed reductions in hypoglycemia events from baseline, though these reductions were not statistically significant compared to placebo. The company believes this was due to a “pronounced study effect” that confounded the primary endpoint.
Importantly for shareholders, the company presented evidence to the FDA that the study observed consistent and clinically significant improvements in time in hypoglycemia by CGM over the entire pivotal period, even if statistical significance was not achieved at Week 24 for this key secondary endpoint. Preliminary data from the OLE further indicate ongoing improvement in glycemic parameters and a notable reduction in use of background standard-of-care therapies among patients receiving ersodetug.
The company shared with the FDA that the unblinded nature of SMBG, essential for patient safety and standard of care, alongside treatment assignment perceptions, may have influenced patient behavior and thus affected hypoglycemia measurement. The FDA acknowledged these challenges and the associated limitations of SMBG in this patient population.
The FDA requested comprehensive study reports and analysis datasets from Rezolute for an independent evaluation. Following this review, a determination will be made as to whether the evidence supports a marketing application for sunRIZE or if additional information is needed.
Notably, the FDA did not dismiss the program based on the missed primary endpoint, and expressed interest in conducting a thorough review. Rezolute expects to update the market on the program’s progress in the second half of 2026.
Potential Price-Sensitive Information
-
Continued FDA Engagement: The FDA’s willingness to review all data, despite the study missing its primary endpoint, leaves open the possibility for regulatory advancement. This is a highly material development, as it keeps the door open for ersodetug’s approval and future commercialization.
-
Positive OLE Results: Ongoing improvements and reductions in background therapy in the OLE suggest durable efficacy, which could be persuasive to regulators.
-
Upcoming Data Disclosures: Key outcomes from the pivotal sunRIZE trial and OLE will be presented at an upcoming scientific conference, which could serve as catalysts for share price movement depending on the nature of the data shared.
-
Next Steps and Timing: Rezolute expects to submit datasets for FDA review and provide a program update in the second half of 2026, marking a critical timeline for investors monitoring regulatory progress.
About Ersodetug
Ersodetug is a fully human monoclonal antibody targeting the insulin receptor, designed to decrease receptor over-activation by insulin and related substances (such as IGF-2) in HI, thereby improving hypoglycemia. Because it acts downstream from the pancreas, ersodetug has the potential to treat all forms of HI, both congenital and acquired. The therapy has been studied in clinical trials and used in real-world cases for both congenital and tumor-related HI.
Management and Advocacy Perspectives
Nevan Charles Elam, CEO and Founder of Rezolute, expressed encouragement that the FDA did not dismiss the sunRIZE program due to the missed primary endpoint and instead showed strong engagement and a willingness to review all data. Julie Raskin, CEO of Congenital Hyperinsulinism International, emphasized the importance of the collaboration between FDA and Rezolute, noting the significant unmet need and hope for new, better-tolerated therapies for the HI community.
Contact Information
Disclaimer
Forward-Looking Statements: This article contains forward-looking statements regarding Rezolute’s plans, regulatory interactions, and the future of the congenital HI program. Actual results may differ materially from those projected due to risks and uncertainties, including but not limited to regulatory outcomes, additional data requirements, and competitive developments. Investors should not place undue reliance on these statements. Rezolute undertakes no obligation to update forward-looking statements except as required by law. For a complete discussion of risks, please refer to Rezolute’s filings with the U.S. Securities and Exchange Commission.
View Rezolute, Inc. Historical chart here
